Neurology and Neurosurgery

61-75 of 91

• 

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  CME/CE

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  • 

    

    Vera Bril, MD

  • 

    

    Jonathan Strober, MD

  0.75 credits

• 

  RestartResume

  Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management

  MinuteCE®

  Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credits

• 

  MinuteCE®

  Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  • 

    

    Hans Katzberg, MD

  1.00 credits 10 episodes

• 

  RestartResume

  Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

  MinuteCE®

  Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credits

• 

  RestartResume

  Ocular to Generalized MG: How and Why the Disease Evolves

  MinuteCE®

  Ocular to Generalized MG: How and Why the Disease Evolves

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credits

• 

  RestartResume

  Living with gMG: Navigating Personal, Professional, and Mental Health Challenges

  MinuteCE®

  Living with gMG: Navigating Personal, Professional, and Mental Health Challenges

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credits
• advertisement

• 

  RestartResume

  A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained

  MinuteCE®

  A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credits

• 

  RestartResume

  New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

  MinuteCE®

  New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credits

• 

  RestartResume

  Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role

  MinuteCE®

  Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credits

• 

  RestartResume

  Diagnostic Advances in gMG: Effective Tools and Techniques

  MinuteCE®

  Diagnostic Advances in gMG: Effective Tools and Techniques

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credits

• 

  RestartResume

  Preventing Myasthenic Crisis: Early Signs and Critical Interventions

  MinuteCE®

  Preventing Myasthenic Crisis: Early Signs and Critical Interventions

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credits

• 

  RestartResume

  Managing Side Effects in FcRn Therapy: Best Practices for gMG

  MinuteCE®

  Managing Side Effects in FcRn Therapy: Best Practices for gMG

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credits
• advertisement

• 

  RestartResume

  Factoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF 

  CME/CE Broadcast Replay

  Factoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF 

  • 

    

    M. Edip Gurol, MD, MSc

  • 

    

    Robin Novakovic, MD

  • 

    

    Shadi Yaghi, MD

  • 

    

    Jeffrey Weitz, MD

  1.50 credits

• 

  RestartResume

  The Safety of Sodium Oxybate in Treating Narcolepsy

  CME/CE

  The Safety of Sodium Oxybate in Treating Narcolepsy

  • 

    

    Clete A. Kushida, MD, PhD

  • 

    

    Sally Ibrahim, MD, FAAP

  0.50 credits

• 

  RestartResume

  Autoantibodies in CIDP: Prevalence and Diagnostic Implications

  MinuteCE®

  Autoantibodies in CIDP: Prevalence and Diagnostic Implications

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credits

• Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• Next